A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Part of paid clinical trials in Fairfax, Virginia.

Sponsor
Avistone Biotechnology Co., Ltd.
Study ID
NCT07538804
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ANS02 — DRUG
    4 dose levels would be explored during the study.

Study Details

This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.

Key Dates

Start date
Jun 9, 2026
Status verified
May 2026
Primary completion
Jun 30, 2029
Completion
Oct 30, 2029

Study Design

Enrollment
294 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ANS02
    ANS02 capsules, oral administration

Primary Outcome Measure

Incidence of Adverse Events (AEs) [ Time Frame: From the time of first dose to 28 days post last dose of ANS02 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteFairfaxVirginia22031-

Find similar trials in Fairfax, VA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Research Site· Fairfax, VA

Related Studies